AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03345290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive tests
Description: Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
Study NCT01229696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Placed At Bifurcation
Description: Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
Study NCT01229696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Placed 5cm Above Bifurcation
Description: Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
Study NCT03284281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tragus stimulator
Description: Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
Study NCT03284281 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Tragus stimulator
Description: No stimulation will be performed
Study NCT02907632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age.
Study NCT02907632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
Study NCT00602758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with cognitive behavioral therapy
Description: Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
Study NCT00602758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy
Description: From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
Study NCT01440257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily
Study NCT01440257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group B)
Study NCT00133549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo administered in a volume of 0.5 ml intramuscularly.
Study NCT00133549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline placebo administered in a volume of 0.5 ml intramuscularly.
Study NCT00133549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNU-IMUNE®23
Description: The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
Study NCT00133549 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNU-IMUNE®23
Description: The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
Study NCT00133549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nine-valent pneumococcal conjugate (PNCRM9)
Description: Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
Study NCT02204475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
Study NCT02204475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
Study NCT02204475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
Study NCT02204475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavarin
Description: Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
Study NCT03642132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + avelumab followed by avelumab + talazoparib
Description: Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib
Study NCT03642132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by talazoparib maintenance
Description: Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib
Study NCT03642132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + bevacizumab followed by bevacizumab
Description: Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab
Study NCT03145818 — intervention group
Intervention type: OTHER
Intervention: VD-HCBS
Description: Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
Study NCT03801031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Topical
Description: Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
Study NCT03801031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Study NCT04508218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplementation powder (Inkospor X-TREME; France)
Description: Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
Study NCT04508218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
Study NCT04508218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional burn care
Description: ROM exercises, stretching, ADL activities and scar management
Study NCT04508218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional burn care
Description: ROM exercises, stretching, ADL activities and scar management
Study NCT00572130 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 1
Description: Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
Study NCT00572130 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 2
Description: Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
Study NCT03615040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2.
Study NCT03615040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
Study NCT02101710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elantan SR 60 mg
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Study NCT02101710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdur SR 60 mg
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Study NCT00349050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laboratory pain assessment
Description: Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
Study NCT00349050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS.
Study NCT04430595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR T cells
Description: Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
Study NCT02317744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and bupropion combination
Study NCT02317744 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Study NCT03549832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg oral pills
Study NCT03549832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Description: Simeprevir 150 mg oral pills
Study NCT03549832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Daclatasvir 60 mg oral pills
Study NCT03549832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 200 mg oral pills
Study NCT03549832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Ombitasvir/paritaprevir/ritonavir oral pills
Study NCT02269085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I.
Study NCT02269085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I.
Study NCT02269085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
Study NCT04760743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP2001 adjuvanted with alum (RBD 30μg/dose)
Description: Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.
Study NCT04760743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP2001 adjuvanted with alum (RBD 50μg/dose)
Description: Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.
Study NCT04760743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study NCT06445452 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Direct SNAP-Ed
Description: Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
Study NCT06445452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct SNAP-Ed
Description: Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
Study NCT03725241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione Supplement
Description: 1000 mg/day Glutathione
Study NCT03725241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Crystalline cellulose
Study NCT02737891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesofensine/Metoprolol
Description: Tesofensine 0.5 mg + Metoprolol 100 mg
Study NCT02737891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03399396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation for HPV vaccine
Description: The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
Study NCT02857634 — intervention group
Intervention type: DEVICE
Intervention: Cellvizio dual band
Description: Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
Study NCT04257188 — intervention group
Intervention type: PROCEDURE
Intervention: minimally invasive vitrectomy under subtenon anaesthesia
Description: The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
Study NCT04232332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor injection,experimental
Description: Intramuscular injection once on the first day according to dose requirements
Study NCT04232332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,single dose
Description: Intramuscular injection once on the first day according to dose requirements
Study NCT04232332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human nerve growth factor injection,multiple dose
Description: Intramuscular injection once daily for 7 days according to dose requirements
Study NCT04459208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manta
Description: plug-based vascular closure
Study NCT04459208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProGlide
Description: suture-based vascular closure
Study NCT02368561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)
Description: US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
Study NCT03595228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BN-Brachyury plus radiation
Description: MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
Study NCT01639729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Sufentanil IV
Description: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Study NCT01639729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Sufentanil NanoTab Sublingual
Description: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Study NCT01639729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Sufentanil NanoTab Buccal
Description: Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Study NCT01639729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Sufentanil NanoTab Oral
Description: Single Sufentanil NanoTab 15 mcg swallowed (PO)
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: MIPARC will focus on 3 physical activity goals:~1. increasing walking behavior through gradually increasing step goals~2. increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~3. reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group educational sessions
Description: Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling call
Description: To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~1. health check~2. step goal check~3. barrier identification~4. problem solving~5. specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring.
Study NCT01155011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity.